Industry Program

Transforming the Trajectory: Early Inflammation Control as a Path to Lasting Change in Spondyloarthritis Objectives: Persistent inflammation in spondyloarthritis (SpA) drives long-term functional impairment and structural damage. This symposium will review how early intervention and effective therapy may influence disease progression, patient-reported outcomes and quality of life. Recent clinical trial data for bimekizumab will be discussed in the context of deep, rapid control of inflammation as well as sustained disease control and long-term management strategies. Agenda – Saturday 31 October

Objectives: Cytokine-targeted therapies continue to improve the treatment landscape of rheumatic and autoinflammatory diseases. This symposium will focus on the evolving role of IL-1 and IL-6 pathway targeting, highlighting recent clinical evidence and practical experience with olokizumab and goflikicept across adult and pediatric inflammatory disorders. Experts will discuss current challenges in disease management, emerging therapeutic approaches, and the future potential of targeted cytokine inhibition in improving long-term patient care. Agenda – Friday 30 October Chairperson: A/Prof Jose Paulo Lorenzo, Philippines

Crossroads of Inflammation: What Advances in PsA/SpA Mean for Clinical Practice Synopsis: The APEX study evaluated guselkumab in adults with active, erosive psoriatic arthritis and demonstrated meaningful clinical and radiographic benefits through Week 48. Participants met predefined activity and erosive criteria and were randomized to two guselkumab dosing regimens or placebo with crossover at Week 24. By Week 48, both guselkumab schedules showed sustained improvements in ACR20 and ACR50 responses, along with continued suppression of radiographic progression, while patients switched

The Evolving Therapeutic Landscape in Sjögren’s Disease: From Pathophysiology to Clinical Evidence Objectives: Sjögren’s disease carries a profound clinical and psychosocial burden, frequently compounded by delayed diagnosis and inadequate conventional treatments. This live symposium will explore the unmet needs and pathophysiology of Sjögren’s disease, focusing on the central role of B-cell hyperactivity and the rationale for B-cell depletion. Expert faculty will review the mechanisms of action and key clinical data for emerging targeted B-cell depleting therapies that are expanding the

Tacrolimus strategy for Autoimmune real-world in Rheumatic Disease Objectives: Information coming soon.

The significance of IL-6 signal blocking in autoimmune diseases including RA Objectives: At this sponsored symposium, lectures will be provided by Japanese and Korean opinion leaders on the importance of blocking IL-6 signaling in autoimmune diseases, particularly RA. Agenda – Friday 30 October Chairpersons: Prof Tsutomu Takeuchi, Japan and Prof Sang-heon Lee, Republic of Korea 1730-1755 Current Landscape and Clinical Experience of IL-6 Receptor Inhibition in Korean RA Patients Prof Chan-bum Choi, Republic of Korea 1755-1820 The Efficacy of IL-6

From Evidence to Confidence: Real-world Clinical Experience with Biosimilars in Europe Objectives: Norway was one of the first countries to implement widespread biosimilar use, led by pioneering research such as the NOR-SWITCH study. This session features Professor Tore K. Kvien, who will share his extensive, decade-long experience with biosimilars in clinical practice. The discussion will move beyond theoretical benefits to focus on long-term real-world data, the evolution of clinician and patient perspectives, and the practical “Experience” that has shaped current